TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15193678
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg twice daily (per-protocol analysis)
Study: 10411250
Drug: Low-dose methyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methyl prednisolone sodium succinate (MPSS) 1 mg/kg
Study: 10411250
Drug: Low-dose methyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methyl prednisolone sodium succinate (MPSS)
Study: 7550814
Drug: Trivalent subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent subvirion influenza virus vaccine
Study: 6990861
Drug: Cimetidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.0 g daily) for four weeks
Study: 30215583
Drug: Control commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control commercial vaccine
Study: 10583317
Drug: Lysine vasopressin
Normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine vasopressin (LVP) administration with minimal dose of GH-RH (0.035 microg/kg BW)
Study: 10583317
Drug: Lysine vasopressin
Normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine vasopressin (LVP) administration with maximal dose of GH-RH (100 microg)
Study: 10583317
Drug: Lysine vasopressin
Normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine vasopressin (LVP) administration with arginine (30 g over 30 min)
Study: 10583317
Drug: Lysine vasopressin
Normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine vasopressin (LVP) administration with clonidine (150 microg)
Study: 10583317
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administration
Study: 7589051
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem LP 300 mg
Study: 29161998
Drug: MMT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMT plus CRT (Cognitive Rehabilitation Treatment) for two months
Study: 26923256
Drug: Donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 23 mg
Study: 25530384
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg doxazosin XL
Study: 25530384
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg doxazosin XL
Study: 25530384
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg doxazosin XL (group 1b)
Study: 25530384
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg doxazosin XL (group 1b)
Study: 19446151
Drug: Dispersible tablet
Normalized name: Aspirin 75 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet formulation of arbidol 200 mg
Study: 19446151
Drug: Branded capsule
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded capsule formulation of arbidol 200 mg
Study: 17224848
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of lopinavir/ritonavir (800/200 mg or 400/100 mg)
Study: 17224848
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of lopinavir/ritonavir
Study: 17224848
Drug: Soft-gelatin capsule
Normalized name: ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Soft-gelatin capsule (SGC) formulation of lopinavir/ritonavir
Study: 15042010
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 microg every 4 hours for 24 hours)
Study: 15042010
Drug: Intra-amniotic PGF(2alpha)
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic PGF(2alpha) (40 mg followed by oxytocin infusion)
Study: 8192104
Drug: Acivicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acivicin 60 mg/m2 as a continuous intravenous infusion over 72 hours, repeated every 28 days
Study: 8192104
Drug: Etoposide 120
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 120 mg/m2 daily on days 1, 2, and 3 and cisplatin 60 mg/m2 intravenously on day 1, repeated every 28 days
Study: 3300325
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy and No therapy
Study: 22020244
Drug: Pre-hospital cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital cooling using a rapid infusion of up to two litres ice-cold Hartmann's solution (82 patients)
Study: 15681958
Drug: S-Caine Patch
Normalized name: Comfort Caine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Caine Patch
Study: 12958723
Drug: Anticoagulation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation group (Group A) - Heparin intravenously with target aPTT 50-70 seconds
Study: 12958723
Drug: Non-anticoagulation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anticoagulation group (Group B) - No intravenous heparin
Study: 1990794
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of intravenous verapamil
Study: 1990794
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 10% intravenous calcium chloride followed by 10 mg of intravenous verapamil
Study: 1990794
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.9% intravenous sodium chloride followed by 10 mg of intravenous verapamil
Study: 1990794
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 10% intravenous calcium chloride followed by 4 ml of 0.9% intravenous sodium chloride
Study: 6848891
Drug: Thymectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymectomy with azathioprine therapy for 1 year
Study: 6848891
Drug: Thymectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thymectomy without azathioprine therapy for 1 year
Study: 22196293
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone via iontophoresis
Study: 22196293
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone injection
Study: 22196293
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg triamcinolone injection
Study: 20303788
Drug: Omega-3 fish
Normalized name: Omega-3 Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fish oil supplementation (2.1 g/day) for 90 days
Study: 17673448
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy (aspirin plus clopidogrel)
Study: 14730323
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy followed by angioplasty after 3 months (Med-PTRA)
Study: 7893284
Drug: bezafibrate 200
Normalized name: bezafibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 200 mg 3 times a day
Study: 25738345
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (CAF + CTG and CAF)
Study: 19116603
Drug: MPSV4 (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPSV4 (licensed unconjugated quadrivalent polysaccharide vaccine)
Study: 15022127
Drug: pressurized metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurized metered dose inhaler and valved holding chamber (pMDI VHC)
Study: 363347
Drug: Subdermal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal implants of levonorgestrel
Study: 363347
Drug: Subdermal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal implants of norgestrel
Study: 22046961
Drug: BUD/FORM 160/4.5 μg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FORM 160/4.5 μg, two inhalations twice daily
Study: 22046961
Drug: BUD 200 μg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD 200 μg, two inhalations twice daily
Study: 15347715
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 20 mg/kg every 12 hours for 48-72 hours
Study: 15347715
Drug: Hepatobiliary scintigraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatobiliary scintigraphy after UDCA treatment
Study: 9539282
Drug: Continuous daily
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10)
Study: 9539282
Drug: Daily transdermal
Normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily transdermal 17beta‐estradiol 50 microg (group B, N=9)
Study: 2263919
Drug: Pulsed ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed ultrasound (1:9, 0.5 watt/cm2 at 1 MHz, for 10 min) 3 days a week for 4 weeks, then twice weekly for 4 weeks, and once weekly for the following 4 weeks.
Study: 2263919
Drug: Placebo-ultrasound (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-ultrasound (standard treatment with paste impregnated bandage and self-adhesive elastic bandage).
Study: 23497350
Drug: medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical nutrition therapy + advice to consume at least two pieces of fruit a day (high‐fruit)
Study: 23497350
Drug: medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical nutrition therapy + advice to consume no more than two pieces of fruit a day (low‐fruit)
Study: 16948990
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (1.5 g intravenous for 20 minutes)
Study: 16948990
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous solution for 20 minutes)
Study: 14613735
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day) for 3 months
Study: 10586340
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg once daily orally (n = 29)
Study: 10586340
Drug: Formestane 250
Normalized name: formestane 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane 250 mg once every two weeks by intramuscular injection (n = 31)
Study: 1657128
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of MAb C23 (5 to 80 mg)
Study: 1657128
Drug: Three infusions
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three infusions of MAb C23 (60, 20, and 20 mg at 1-week intervals)
Study: 6961425
Drug: Pyridoxine (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (vitamin B-6) treatment
Study: 30442217
Drug: Group psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychological treatment program (8 one-hour sessions, cognitive-behavioral approach)
Study: 27122490
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 500 IU hCG (n=7)
Study: 8225149
Drug: Captopril (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-50 mg daily)
Study: 3517926
Drug: Stanozolol 5
Normalized name: stanozolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol 5 mg twice daily for six months
Study: 30348178
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (5 mg.kg-1)
Study: 27996026
Drug: Public reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public reporting of prescriptions
Study: 25509236
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous (IV) paracetamol 20 min before the operation
Study: 25509236
Drug: 1 cc
Normalized name: BD Needle SG 1 cc 27g 5/8"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cc normal saline (placebo) 20 min before the operation
Study: 22938071
Drug: Conventional Language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Language Therapy (CLT)
Study: 20712134
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of betahistine (16 mg tablet)
Study: 20712134
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of betahistine (16 mg tablet)
Study: 12812866
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels of 35 microU/ml
Study: 12812866
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels of 85 microU/ml
Study: 12812866
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels of 25 microU/ml
Study: 10827410
Drug: 0.5 x
Normalized name: PAD,FOAM 0.5 X 18 X 72IN BIACARE #5302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 x 10(6) IU/m(2) of rIFN‐gamma (low‐dose group)
Study: 10827410
Drug: 1.5 x
Normalized name: lisocabtagene maraleucel 1.5 x 10exp6 to 70 x 10exp6 cell/mL INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 x 10(6) IU/m(2) of rIFN‐gamma (high‐dose group)
Study: 10827410
Drug: rIFN‐gamma therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma therapy (both dosages)
Study: 22205315
Drug: Entrée portion
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entrée portion sizes of 100, 160, 220, 280, 340, and 400 g
Study: 18598831
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution nasal irrigation
Study: 6238829
Drug: mianserin 10
Normalized name: mianserin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 10 mg
Study: 6238829
Drug: amitriptyline 10
Normalized name: amitriptyline 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline 10 mg
Study: 8473720
Drug: amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline 50 mg
Study: 6238829
Drug: zimeldine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: zimeldine 200 mg
Study: 6238829
Drug: ethanol 1
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethanol 1 g/kg bodyweight
Study: 29220609
Drug: SSF‐Assessment Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSF‐Assessment Group Therapy
Study: 29220609
Drug: Usual Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Assessment Group Therapy
Study: 29516964
Drug: Rendezvous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rendezvous therapy (radiotherapy with local delivery of nimustine and oral temozolomide)
Study: 29516964
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (radiotherapy with concomitant and adjuvant temozolomide)
Study: 24647023
Drug: Metronidazole (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (10-day course, oral)
Study: 22017387
Drug: Complex anthroposophic
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex anthroposophic remedy (Apis regina tota GL D4, Argentum metallicum D5, Ovaria bovis GL D4), 3 × 10 globuli daily for 12 weeks
Study: 16245418
Drug: Fenspiride 160
Normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride 160 mg/day for 6 months
Study: 12476070
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy for 14 days
Study: 9829492
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron therapy (Ferric saccharate, 100 mg dose, administered postdialysis on five consecutive dialysis sessions for 2 weeks)
Study: 9829492
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid therapy (300 mg dose, administered thrice a week for 8 weeks)
Study: 9829492
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Control I and Control II, haematocrit > 30%, no adjuvant therapy)
Study: 2667926
Drug: Continuous basal-rate
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous basal-rate intravenous insulin infusion
Study: 2667926
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily injections of ultralente insulin
Study: 2667926
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily injections of lente insulin
Study: 996681
Drug: 220 mg
Normalized name: urea 220 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg zinc sulphate
Study: 996681
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bicitropeptide
Study: 7014104
Drug: Amineptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine (mean 180 mg, range 100-300 mg)
Study: 7014104
Drug: Clomipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (mean 84 mg, range 50-150 mg)
Study: 29356603
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dexketoprofen trometamol (DKT)
Study: 29356603
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vitamin C (PLACEBO)
Study: 27821382
Drug: Intravenous eculizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous eculizumab (900 mg/day)
Study: 22168326
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical adapalene gel for 4 weeks (Group A)
Study: 22168326
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical adapalene gel and 600 mg oral faropenem for 2 weeks followed by 0.1% topical adapalene gel alone for 2 weeks (Group B)
Study: 22168326
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical adapalene gel and 600 mg oral faropenem for 4 weeks (Group C)
Study: 18842788
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (daily tablet containing 15 micronutrients at just above the recommended nutrient intake)
Study: 8923125
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg twice a day)
Study: 1679243
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg (single oral dose)
Study: 6415364
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment with 4 mg oestradiol
Study: 6415364
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment with 2 mg oestradiol
Study: 6415364
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment with 1 mg oestradiol
Study: 6415364
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of hormone treatment
Study: 30320964
Drug: Belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 10 mg/kg every 28 days plus standard therapy
Study: 26294070
Drug: Low-dose isoflavone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isoflavone aglycone (25 mg/day)
Study: 17400850
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered simultaneously
Study: 17400850
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered 24 hours apart
Study: 12729424
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg intravenously every 12 hours for 2 days followed by 200 mg intravenously every 24 hours or a 200‐mg oral solution every 12 hours)
Study: 12729424
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg intravenously or orally every 24 hours)
Study: 8952557
Drug: Tetracycline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (20 mg/kg [maximum of 2 g] in 50 mL of normal saline)
Study: 8952557
Drug: Bleomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (1 U/kg [maximum of 60 U] in 50 mL of normal saline)
Study: 8952557
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tetracycline (20 mg/kg [maximum of 2 g] in 40 mL of normal saline) and bleomycin (1 U/kg [maximum of 60 U] in 30 mL of normal saline)
Study: 7381634
Drug: Cloxacillin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin administered intravenously for ten days
Study: 7381634
Drug: Carbenicillin plus
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin plus gentamicin administered intravenously for ten days
Study: 25320597
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone 8mg and ondansetron 4mg